Rezolute to participate in upcoming investor conferences

REDWOOD CITY, Calif., Sept.

02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc.

NASDAQ:RZLT (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management…